N-(4-(4-(677 million mumu 6.7 million mu 96 6 96 96 9595959595959595 lamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlamlam_a lambda_kappa_form, this treatment. Y cancer

摘要

Here we reveal that the mu951959595959595959595, including a (L) - malic acid (D) Salts, a mixture of malate, malate (LD), and alpha_and crystalline and non-crystalline forms of mu_lambda_salt.It has also been revealed that the malate pharmaceutical composition includes at least one N-(4-(670 million mu_lambda zeta_) kappa_-4-(I)) n-phenyl-(4-fluorophenyl) - kappa_ 1,1-delta_kappa alpha p_a alpha u_delta_, the method of Administration for cancer treatment is derived from at least one N-(4-malic acid acid salt [(u e e theta_lambda zeta_) 670;__lambda_-4-oxygen} I] phenyl) -N'-(phenyl) 4 fluoro phenyl) - 1, 1 - Delta, kappa alpha, rho, beta, and alpha.